Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H3N2 Influenza Challenge Pilot Study
NCT07063849Phase 1Active, not recruiting
- Start
- May 2025
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial. Primary endpoints: Frequency of Adverse Events (AEs) and Serious Adverse Events (SAE), Frequency of AE and SAE post-inpatient discharge up to 3 months and 7 more. Started May 2025; status: active, not recruiting.
Beyond the preview
Go deeper on NCT07063849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07063849.